DOCSLIB.ORG

List of Running Issuance Programs (03/09/2021)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Running Issuance Programs (03/09/2021) Financial Markets Department Payments and securities Securities Settlement Unit boulevard de Berlaimont 14 – BE-1000 Brussels Phone : +32 2 221 22 17 – Fax : +32 2 221 31 20 VAT BE 0203.201.340 – RLP Brussels Account number : BE36 0016 2658 1781 [email protected] Ref: Issuanceprograms List of Running Issuance Programs (28/09/2021) Type of issuance program: 1. Treasury bills IP Issuer Paying Agent Term STEP Id Start End Amount to be issued Outstanding 2155.LEASINVEST REAL ESTATE NV/SA BBRUBEBB010.ING 136 - 11/10/1999 31/12/9999 110 000 000 EUR Program name: TB LEASINVEST REAL ESTATE BELGIUM S.A. 2253.SANOMA CORPORATION BBRUBEBB010.ING 268 Short 29/12/2003 31/12/9999 300 000 000 EUR Program name: TB SANOMA BELGIUM S.A. 2265.SANDVIK AB BBRUBEBB010.ING 387 - 04/03/2005 31/12/9999 500 000 000 EUR Program name: TB SANDVIK AB BELGIUM S.A. 2266.SANDVIK TREASURY AB BBRUBEBB010.ING 388 - 04/03/2005 31/12/9999 500 000 000 EUR Program name: TB SANDVIK TREASURY AB BELGIUM S.A. 2305.STAD AALST BBRUBEBB010.ING 450 Short 18/01/2007 31/12/9999 50 000 000 EUR 18 250 000,00 EUR Program name: TB STAD AALST BELGIUM S.A. 2327.COMMUNE DE CHAUDFONTAINE BBRUBEBB010.ING 493 - 22/01/2008 31/12/9999 75 000 000 EUR Program name: TB COMMUNE DE CHAUDFONTAINE BELGIUM S.A. 2357.STAD ZOTTEGEM BBRUBEBB010.ING 558 Short 12/06/2009 31/12/9999 30 000 000 EUR Program name: TB STAD ZOTTEGEM BELGIUM S.A. 2358.PROVINCIE VLAAMS-BRABANT BBRUBEBB010.ING 559 Short 29/06/2009 31/12/9999 25 000 000 EUR Program name: TB PROVINCIE VLAAMS-BRABANT BELGIUM S.A. 2380.STAD RONSE BBRUBEBB010.ING 615 - 16/09/2010 31/12/9999 20 000 000 EUR 5 000 000,00 EUR Program name: TB STAD RONSE BELGIUM S.A. 2412.STAD LIER BBRUBEBB010.ING 694 Short 04/05/2012 31/12/9999 45 000 000 EUR Program name: TB STAD LIER BELGIUM S.A. 2190.STAD GENT BBRUBEBB010.ING 698 - 05/06/2012 31/12/9999 150 000 000 EUR 20 000 000,00 EUR Program name: TB STAD GENT BELGIUM S.A. 2416.OCMW GENT BBRUBEBB010.ING 699 Short 05/06/2012 31/12/9999 15 000 000 EUR Program name: TB OCMW GENT BELGIUM S.A. 2418.GEMEENTE HEUSDEN-ZOLDER BBRUBEBB010.ING 711 Short 14/08/2012 31/12/9999 25 000 000 EUR Program name: TB GEMEENTE HEUSDEN-ZOLDER BELGIUM S.A. IP = our internal number of an issuance program / STEP = Short-Term European Paper Split by type of issuance program - Page 1 of 29 IP Issuer Paying Agent Term STEP Id Start End Amount to be issued Outstanding 2024.COMMUNAUTE FRANCAISE DE BELGIQUE BBRUBEBB010.ING 746 Program name: TB COMMUNAUTE FRANCAISE DE Short 13/02/2013 31/12/9999 750 000 000 EUR BELGIUM S.A. BELGIQUE 2250.SOC WAL CREDIT SOCIAL (GARANTIE REG.WAL) BBRUBEBB010.ING 755 - 28/03/2013 31/12/9999 250 000 000 EUR 168 500 000,00 EUR Program name: TB SWCS (GARANTIE REG.WAL.) BELGIUM S.A. 2441.HOGESCHOOL GENT BBRUBEBB010.ING 785 - 04/07/2013 31/12/9999 40 000 000 EUR 23 000 000,00 EUR Program name: TB HOGESCHOOL GENT BELGIUM S.A. 2358.PROVINCIE VLAAMS-BRABANT BBRUBEBB010.ING 808 Long 06/12/2013 31/12/9999 130 000 000 EUR 12 750 000,00 EUR Program name: TB PROVINCIE VLAAMS-BRABANT BELGIUM S.A. 2449.STAD AALST (POOL) BBRUBEBB010.ING 821 Program name: POOLED NOTES FLEMISH CITIES & Long 20/12/2013 20/12/2023 43 500 000 EUR 43 500 000,00 EUR BELGIUM S.A. MUNICIP. 2363.STAD BRUGGE BBRUBEBB010.ING 937 - 14/07/2015 12/12/2024 100 000 000 EUR 11 000 000,00 EUR Program name: TB STAD BRUGGE BELGIUM S.A. 2505.UNIVERSITEIT GENT BBRUBEBB010.ING 1038 - 18/11/2016 31/12/9999 300 000 000 EUR 50 000 000,00 EUR Program name: UNIVERSITEIT GENT BELGIUM S.A. 2513.Essity Aktiebolag (publ) BBRUBEBB010.ING 1055 Short 23/03/2017 31/12/9999 1 200 000 000 EUR 492 000 000,00 EUR Program name: TB ESSITY AKTIEBOLAG (PUBL) BELGIUM S.A. 2001.N.M.B.S. BBRUBEBB010.ING 1084 Short 17/07/2017 31/12/9999 1 500 000 000 EUR Program name: TB NMBS NV BELGIUM S.A. 2363.STAD BRUGGE BBRUBEBB010.ING 1130 - 03/05/2018 31/12/9999 100 000 000 EUR 18 500 000,00 EUR Program name: TB STAD BRUGGE BELGIUM S.A. 2532.WATER-LINK BBRUBEBB010.ING 1134 - 08/06/2018 31/12/9999 75 000 000 EUR Program name: TB WATER-LINK BELGIUM S.A. 2357.STAD ZOTTEGEM BBRUBEBB010.ING 1165 Long 18/12/2018 31/12/9999 40 000 000 EUR 5 500 000,00 EUR Program name: TB STAD ZOTTEGEM BELGIUM S.A. 2412.STAD LIER BBRUBEBB010.ING 1198 - 25/09/2019 31/12/9999 45 000 000 EUR Program name: TB STAD LIER BELGIUM S.A. 2558.ELIA TRANSMISSION BELIUM NV/SA BBRUBEBB010.ING 1221 Short 18/05/2020 31/12/9999 300 000 000 EUR 30 000 000,00 EUR Program name: TB ELIA TRANSMISSION BELGIUM SA/NV BELGIUM S.A. 2166.ENI FINANCE INTERNATIONAL S.A. ENIBBEBBXXX.BANQUE ENI 1199 Short 0000733 03/10/2019 31/12/9999 4 000 000 000 EUR 519 680 844,96 EUR Program name: TB ENI FINANCE INT. S.A. 2020.SUEZ-TRACTEBEL S.A. GEBABEBB36A.BNP 3 - 21/05/1996 31/12/9999 350 000 000 EUR Program name: TB SUEZ-TRACTEBEL PARIBAS FORTIS 2024.COMMUNAUTE FRANCAISE DE BELGIQUE GEBABEBB36A.BNP 5 - 14/06/2000 31/12/9999 750 000 000 EUR Program name: TB COMMUNAUTE FRANCAISE PARIBAS FORTIS 2006.AGC EUROPE SERVICES GEBABEBB36A.BNP 32 Short 28/06/1999 31/12/9999 123 900 000 EUR Program name: TB AGC EUROPE SERVICES PARIBAS FORTIS 2015.EXTENSA GROUP N.V. GEBABEBB36A.BNP 44 - 05/11/1993 31/12/9999 100 000 000 EUR Program name: TB EXTENSA PARIBAS FORTIS 2090.STAD HASSELT GEBABEBB36A.BNP 106 Short 08/07/1999 31/12/9999 100 000 000 EUR Program name: TB STAD HASSELT PARIBAS FORTIS 2162.FINANCIERE AGACHE GEBABEBB36A.BNP 153 Short 27/10/1999 31/12/9999 700 000 000 EUR 2 000 000,00 EUR Program name: TB FINANCIERE AGACHE PARIBAS FORTIS IP = our internal number of an issuance program / STEP = Short-Term European Paper Split by type of issuance program - Page 2 of 29 IP Issuer Paying Agent Term STEP Id Start End Amount to be issued Outstanding 2092.R.S.V.Z. GEBABEBB36A.BNP 235 Short 19/01/2001 31/12/9999 223 000 000 EUR Program name: TB RSVZ PARIBAS FORTIS 2259.DAIKIN EUROPE COORD.CENTER NV GEBABEBB36A.BNP 356 Short 17/09/2004 31/12/9999 150 000 000 EUR Program name: TB DAIKIN EUROPE C.CENTER PARIBAS FORTIS 2280.WIENERBERGER FINANZ SERVICE GMBH GEBABEBB36A.BNP 407 Program name: TB WIENERBERGER FINANZ SERVICE - 09/12/2005 31/12/9999 200 000 000 EUR 24 000 000,00 EUR PARIBAS FORTIS GMBH 2147.KINEPOLIS GROUP GEBABEBB36A.BNP 578 Short 20/11/2009 31/12/9999 50 000 000 EUR Program name: TB KINEPOLIS GROUP PARIBAS FORTIS 2026.REGION WALLONNE GEBABEBB36A.BNP 591 - 22/02/2010 31/12/9999 1 250 000 000 EUR 117 000 000,00 EUR Program name: TB REGION WALLONNE PARIBAS FORTIS 2379.HAMON & CIE (INTERNATIONAL) S.A. GEBABEBB36A.BNP 614 Short 30/08/2010 31/12/9999 75 000 000 EUR Program name: TB HAMON & CIE (INTERNATIONAL) PARIBAS FORTIS 2186.AQUAFIN NV GEBABEBB36A.BNP 653 - 10/06/2011 18/10/2024 400 000 000 EUR 60 000 000,00 EUR Program name: TB AQUAFIN NV PARIBAS FORTIS 2079.RIJKSDIENST VOOR SOCIALE ZEKERHEID GEBABEBB36A.BNP 683 Short 22/02/2012 31/12/9999 615 000 000 EUR Program name: TB RSZ PARIBAS FORTIS 2384.TESSENDERLO GROUP NV GEBABEBB36A.BNP 715 Short 10/09/2012 31/12/9999 200 000 000 EUR Program name: TB TESSENDERLO CHEMIE PARIBAS FORTIS 2164.ACKERMANS & VAN HAAREN N.V. GEBABEBB36A.BNP 716 Short 05/11/1999 31/12/9999 200 000 000 EUR 23 500 000,00 EUR Program name: TB ACKERMANS VAN HAAREN NV PARIBAS FORTIS 2158.DEME COORDINATION CENTER N.V. GEBABEBB36A.BNP 722 Short 04/10/2012 31/12/9999 125 000 000 EUR 60 000 000,00 EUR Program name: TB DEME C.CENTER PARIBAS FORTIS 2190.STAD GENT GEBABEBB36A.BNP 841 Long 29/04/2014 31/12/9999 150 000 000 EUR 20 000 000,00 EUR Program name: TB STAD GENT PARIBAS FORTIS 2200.IKA GARANTIE IKA GEBABEBB36A.BNP 929 - 29/06/2015 31/12/9999 112 500 000 EUR 56 939 091,00 EUR Program name: TB IKA PARIBAS FORTIS 2186.AQUAFIN NV GEBABEBB36A.BNP 945 - 17/09/2015 31/12/9999 500 000 000 EUR 144 000 000,00 EUR Program name: TB AQUAFIN PARIBAS FORTIS 2383.LVMH FINANCE BELGIQUE SA GEBABEBB36A.BNP 951 Short 21/10/2015 31/12/9999 12 000 000 000 EUR 525 500 000,00 EUR Program name: TB LVMH FINANCE BELGIQUE S.A. PARIBAS FORTIS 2329.UCB SA GEBABEBB36A.BNP 981 Short 28/04/2016 31/12/9999 500 000 000 EUR Program name: TB UCB SA PARIBAS FORTIS 2500.BESIX GROUP SA GEBABEBB36A.BNP 998 Short 23/06/2016 31/12/9999 100 000 000 EUR 100 000 000,00 EUR Program name: TB BESIX GROUP SA PARIBAS FORTIS 2392.ORES SCRL GEBABEBB36A.BNP 1023 - 26/09/2016 31/12/9999 550 000 000 EUR Program name: TB ORES SCRL PARIBAS FORTIS 2055.SOLVAY S.A.
Load more

Recommended publications
  • UCB SA (Incorporated with Limited Liability in Belgium) As Issuer
    Base Prospectus dated 8 March 2021 UCB SA (incorporated with limited liability in Belgium) as Issuer EUR 5,000,000,000 Euro Medium Term Note Programme Due from one month from the date of original issue This base prospectus (the “Base Prospectus”) relating to the EUR 5,000,000,000 Euro Medium Term Note Programme (the “Programme”) of UCB SA, a limited liability company (société anonyme) incorporated under the laws of Belgium, having its registered office at Allée de la Recherche 60, B-1070 Brussels and registered with the Crossroads Bank for Enterprises under number 0403.053.608 (“UCB”, or the “Issuer”) is valid, for the purpose of the admission to trading and listing of the Notes (as defined below) on the regulated market of Euronext Brussels or on another regulated market in the European Economic Area (the “EEA”), for a period of twelve months from the date of approval. Any Notes issued under the Programme are issued subject to the provisions set out herein. Under the Programme, the Issuer, subject to compliance with all relevant laws, regulations and directives, may from time to time issue Euro Medium Term Notes (the “Notes”) as may be agreed between the Issuer and the relevant Dealer (as defined below). The minimum Specified Denomination of Notes shall be EUR 100,000 (or its equivalent in other currencies).The maximum aggregate nominal amount of Notes outstanding will not at any time exceed EUR 5,000,000,000 (or the equivalent in other currencies). This Base Prospectus has been approved as a base prospectus for the purposes of Article 8 of Regulation 2017/1129 (as amended, the “Prospectus Regulation”) on 8 March 2021 by the Belgian Financial Services and Markets Authority (the “FSMA”) in its capacity as competent authority in accordance with Article 20 of the Prospectus Regulation.
    [Show full text]
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • Integrated Annual Report 2020
    Amber, living with psoriasis INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE Welcome to our Integrated Annual Report 2020! Our Integrated Annual Report 2020 – Adapting for Better Care – aims to provide all interested stakeholders with the best pos- sible information on how UCB is creating value for patients with severe diseases and about how we care for our employees, for communities, and for our planet, now and into the future. About this report This Integrated Annual Report 2020 includes the management report in accordance with article 12 of the Royal Decree of 14 November 2007 relating to the obligations of issuers of finan- cial instruments admitted to trading on a regulated market. All information required to be included in such management report pursuant to articles 3:6 and 3:32 of the Belgian Code of Com- panies and Associations (i.e. Corporate Governance Statement – Remuneration Report included -, Business Performance Review and UCB’s Statement on extra-financial1 information) is reported throughout all different sections of this Integrated Annual Re- port. This Integrated Annual Report together with the materiality assessment have been prepared in accordance with the Global Reporting Standards core option and extra-financial information is audited by a third party. 1 ‘Extra-financial’ is the term used by UCB for information commonly referred to as ‘non-financial’. UCB | Integrated Annual Report 2020 3 Index Key Figures 6 UCB At a Glance 8 Letter to our stakeholders
    [Show full text]
  • September 2020 Introduction to Umicore We Are a Global Materials Technology and Recycling Group
    Umicore Investor Presentation September 2020 Introduction to Umicore We are a global materials technology and recycling group One of three global A leading supplier of key The world’s leading leaders in emission control materials for rechargeable recycler of complex waste catalysts for light-duty and batteries used in electrified streams containing heavy-duty vehicles and transportation and portable precious and other for all fuel types electronics valuable metals 3 With a unique position in clean mobility materials and recycling Internal Plug-In Hybrid Combustion Engine Electric Vehicle Umicore provides: Umicore provides: Emission control catalysts Battery cathode materials and emission control catalysts Full Electric Vehicle Fuel cells Umicore provides: Umicore provides: Battery cathode materials Electro-catalyst and battery cathode materials Present across all drive trains and offering sustainable closed- loop services 4 Built on sound foundations Supportive Unique business Industry leader in megatrends & model sustainability legislation resource scarcity more stringent emission control electrification recyclingrecycling of the automobile We help improve air quality, make electrified transport possible and tackle resource scarcity 5 5 With a robust financial performance and a global presence Key figures (FY 2019) Adj. Revenues EBITDA € 3.4 bn € 753 m Adj. EBIT ROCE € 509 m 12.6% 40% - Europe Revenues* by Clean geography 14% - North America mobility and R&D Recycling 6% of 4% - South America 75% of revenues revenues 39% - Asia-Pacific
    [Show full text]
  • Annual Report 2012
    Annual Report 2012 Groupe Bruxelles Lambert Online additional information www.gbl.be Investors information Additional information can be found on Online registration in order to receive the website, among which: investors information (notices, • Historical information of GBL press releases, ...) through the • The yearly and half-yearly reports and Company website. also quarterly press releases • Adjusted net assets on a weekly basis • The press releases • The portfolio Investor relations Axelle Henry [email protected] Tel.: +32 (0)2 289 17 17 Annual Report 2012 Overview of GBL 2 THE ESSENTIAL Message from the Chairman of the Board of Directors 4 Message from the CEO and the Managing Directors 6 Value creation 8 Highlights 10 Key fi gures 12 Risk management 14 Corporate and Social Responsibility 16 Evolution of the share in 2012 18 SHAREHOLDERS Distribution policy and proposed dividend 19 INFORMATION AND Investor relations 19 MARKET DATA Financial calendar 19 Market data and indicators 20 Resolutions proposed to Shareholders 22 Portfolio and adjusted net assets 24 ACTIVITY REPORT Consolidated fi gures IFRS (economic analysis) 28 Strategic investments 34 Total 34 GDF SUEZ 36 Lafarge 38 Pernod Ricard 40 Imerys 42 Suez Environnement 44 Breakdown of turnover by geographical area 46 Financial Pillar 47 Ergon Capital Partners 48 Sagard 49 Consolidated fi nancial statements 52 ACCOUNTS Condensed statutory balance sheet and income statement 100 AT 31 DECEMBER 2012 Dividend policy 102 Historical data 103 Corporate governance statement 106 CORPORATE Board of
    [Show full text]
  • Umicore Intends to Launch Squeeze-Out for Remainder of Agosi
    Press release 3 February 2021 – 08:30 am CET Umicore intends to launch squeeze-out for remainder of Agosi shares Umicore has informed its listed subsidiary Allgemeine Gold- und Silberscheideanstalt AG (“Agosi”) that it intends to purchase the 8.8 % shares it does not yet own from Agosi’s minority shareholders through a merger squeeze-out in accordance with German law. To determine the cash compensation for Agosi’s minority shareholders, a valuation of Agosi will be carried out by an independent valuer appointed by Umicore and a court-appointed auditor. Following a squeeze-out and subsequent delisting, Umicore would have flexibility to consider strategic options for the Jewelry & Industrial Metals activities within Agosi. These activities perform well from a commercial and financial point of view and Umicore wants to explore the best conditions for their further development. Umicore expects that the merger squeeze-out would be resolved upon by the general meeting of Agosi in the second or third quarter of 2021. Note to the editor: Umicore acquired Agosi upon the acquisition of the Precious Metals Group (“PMG”) in 2003 and currently holds 91.2 % of its shares. Agosi shares are listed on the Munich Freiverkehr stock exchange. Agosi, headquartered in Pforzheim, Germany, has an international presence and offers the full precious metals cycle and other precious metals services for the jewelry and coin industries, as well as for various industrial applications in electrical engineering, in automotive, in the chemical industry and in medical technology. Agosi’s activities are integrated in Umicore’s Jewelry & Industrial Metals business unit and one Agosi subsidiary is part of Umicore’s Electroplating business unit.
    [Show full text]
  • Dynavax Announces Full Enrollment of Phase II/III AIC Trial
    Dynavax Announces Full Enrollment of Phase II/III AIC Trial BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that its Phase II/III clinical trial of AIC for ragweed allergy, which started in late February 2004, has been fully enrolled. The double blind, placebo controlled study involves 462 subjects at 30 sites in the U.S. and will be completed over the next 18 months. The immunization schedule, consisting of six injections over six weeks, will be completed by June. The clinical trial is being conducted in collaboration with UCB Pharma, a European pharmaceutical company that markets XYZAL® and developed ZYRTEC®, the leading prescription anti- allergy drug worldwide. Dynavax and UCB signed a global licensing and commercialization agreement covering ragweed and grass allergy immunotherapies in February 2004. The primary endpoint of the Phase II/III ragweed study will be nasal symptoms scores after the second ragweed season in the late summer and early fall of 2005, with secondary endpoints assessing symptoms, medication use and quality of life in both the first and second year. A blinded interim analysis will be made in late 2004 to assess safety and the appropriateness of commencing a one-year Phase III trial in early 2005. "The collaboration with UCB has been very effective, with both organizations working diligently to advance our ragweed program," said Dr. Dino Dina, president and CEO of Dynavax. "The rapid enrollment of our ragweed trial, particularly given its size and stringent enrollment criteria, is an early indication of the level of interest that both investigators and patients have in this therapy.
    [Show full text]
  • Building Leading Companies Through Long-Term Engaged and Responsible Ownership
    Building leading companies through long-term engaged and responsible ownership Groupe Bruxelles Lambert Half-yearly report July 30, 2020 Privileged information - Regulated information as of June 30, 2020 2 GBL Half-yearly report as of June 30, 2020 Groupe Bruxelles Lambert (“GBL”) is an established investment holding company, with over sixty years of stock exchange listing, a net asset value of EUR 18 billion and a market capitalization of EUR 12 billion as of end of June 2020. GBL is a leading investor in Europe, focused on long-term and sustainable value creation and relying on a stable and supportive family shareholder base. GBL strives to maintain a diversified high-quality portfolio composed of global companies, leaders in their sector, in which it can contribute to value creation by being an engaged professional investor. GBL seeks to provide attractive returns to its shareholders through a combination of a sustainable dividend and growth in its net asset value. GBL is listed on Euronext Brussels (Ticker: GBLB BB; ISIN code: BE0003797140) and is part of the BEL20 index. 3 GBL Half-yearly report as of June 30, 2020 Half-yearly report as of June 30, 2020 Key information for shareholders 4 Message from Ian Gallienne, CEO of GBL Financial calendar • November 4, 2020: Results as of September 30, 2020 5 Key financial data • March 2021: Annual Results 2020 6 Highlights • April 27, 2021: Ordinary General Meeting 2021 8 Organisation chart and net asset value • Early May 2021: First quarter 2021 results 8 Organisation chart as of June 30, 2020 • End July 2021: Half-year 2021 results 8 Net asset value Note: the above-mentioned dates depend on the agenda of the Board of Directors meetings and are thus subject to change.
    [Show full text]
  • Lamotrigine Orally Disintegrating Tablet
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3001-14 Program Step Therapy - Anticonvulsants Medication/Therapeutic Anticonvulsants – Class Depakote®, Depakote ER®, Felbatol, Keppra® , Keppra® XR®, Lamictal®, Lamictal XR®, Lamictal ODT®, lamotrigine extended-release, lamotrigine orally disintegrating tablet, Lyrica, Mysoline, Neurontin®, Onfi, Oxtellar™ XR*, Qudexy XR* (brand and authorized generic), Sabril, Spritam*, Topamax®, Trileptal®, Trokendi® XR*, Zonegran® P&T Approval Date 8/2010, 11/2010, 11/2011, 2/2013, 11/2013, 4/2014, 7/2014, 11/2014, 4/2015, 1/2016, 6/2016, 6/2017, 9/2018, 9/2019, 10/2020, 6/2021 Effective Date 9/1/2021; Oxford only: N/A 1. Background Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. a. Multi-Source Brand Products This program requires a member to try the A-rated generic prior to receiving coverage for Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Lyrica, Mysoline, Neurontin, Onfi, Sabril, Topamax, Trileptal and Zonegran. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the A-rated generic in the previous 6 months, the prescription will process automatically. b. Modified Release Products This program requires a member to try levetiracetam immediate release, levetiracetam extended-release, levetiracetam solution, lamotrigine immediate release, divalproex sodium delayed release, Depakote delayed release, generic valproic acid, Depakene formulations, Depakote sprinkles, divalproex sodium sprinkles, oxcarbazepine or Trileptal prior to coverage of their respective modified release formulations: lamotrigine extended-release, lamotrigine orally disintegrating tablet, Oxtellar XR*, Qudexy XR*, Spritam and Trokendi XR*.
    [Show full text]
  • UMICORE SA (GROUP) Brussels - Belgium | Manufacture of Basic Precious and Other Non- 2020 Ferrous Metals Significant Operations in at Least One Risk Country
    EcoVadis Scorecard www.ecovadis.com UMICORE SA (GROUP) Brussels - Belgium | Manufacture of basic precious and other non- 2020 ferrous metals Significant operations in at least one risk country Publication date: 24 Jul 2020 Valid until: 24 Jul 2021 CSR Performance Insufficient Partial Moderate Advanced Outstanding Average score OVERALL SCORE ENVIRONMENT LABOR & HUMAN ETHICS SUSTAINABLE RIGHTS PROCUREMENT 73 /100 80 /100 80 /100 60 /100 60 /100 99th Weight Weight Weight Weight percentile Overall score distribution Theme score comparison 100 UMICORE SA (GROUP) ENVIRONMENT LABOR & HUMAN 100% 80 73 RIGHTS 60 75% 40 20 50% 50.36 41.55 25% 0% 4.36 3.74 SUSTAINABLE ETHICS 0 0 25 45 65 85 100 PROCUREMENT All companies assessed by EcoVadis in this industry UMICORE SA (GROUP) score All companies assessed by EcoVadis in this industry Strengths and Improvement Areas Environment Weight Strengths (38) Policies Strengths Quantitative objectives set on some relevant issues [i.e. GHG emissions, water] Comprehensive policy on a majority of environmental issues Endorsement of external initiative on environmental issues [i.e. The International Platinum Group Metals Association (IPA), Eurometaux, CIRAF, Fachvereinigung Edelmetalle] Actions Strengths Company-specific emergency preparedness and response procedure regarding local pollution Measures to minimize odor generation in rendering plant operations Control measures to monitor and/or prevent contamination of groundwater Measures to reduce CO2 emissions from transport Formalized procedure related to materials / chemicals management (e.g. storing, handling, transportation) Purchasing of renewable energy Registration of substances to the ECHA Reuse by-products from the process as raw materials or as raw material substitutes in other processes Monitoring of pollutant concentrations into waste gas (e.g.
    [Show full text]
  • Investor Presentation June 2021
    Umicore Investor Presentation June 2021 Introduction to Umicore We are a global materials technology and recycling group One of three global A leading supplier of key The world’s leading leaders in emission control materials for rechargeable recycler of complex waste catalysts for light-duty and batteries used in electrified streams containing heavy-duty vehicles and transportation and portable precious and other for all fuel types electronics valuable metals 3 With a unique position in clean mobility materials and recycling Internal Plug-In Hybrid Combustion Engine Electric Vehicle Umicore provides: Umicore provides: Emission control catalysts Battery cathode materials and emission control catalysts Full Electric Vehicle Fuel cells Umicore provides: Umicore provides: Battery cathode materials Electro-catalyst and battery cathode materials Present across all drive trains and offering sustainable closed- loop services 4 Built on sound foundations Supportive Unique business Industry leader in megatrends & model sustainability legislation resource scarcity more stringent emission control electrification recyclingrecycling of the automobile We help improve air quality, make electrified transport possible and tackle resource scarcity 5 5 Unique position in Automotive Catalysts CATALYSIS Strong growth drivers: Umicore best positioned to Tightening emission norms for capture growth in growing LDV and HDD, in particular in gasoline segment; technology China, Europe and India leader in cGPF platforms in China and Europe Significant value uplift
    [Show full text]
  • Analyst Report KBC Securities
    MORNING NOTE 24 April 2012 Benelux Conference in London, 22 May 2012. Click here to register. Dear client, the Extel Europe 2012 survey will run from 19 March to 4 May. If you appreciate our services, we would be grateful to receive your vote on www.extelsurvey.com in the following categories: Benelux: Country Analysis; Corporate Access; Equity Sales and Trading/Execution. Thank you. CONTENTS Company / Sector Comment Recommendation Price Target Price Cofinimmo Student housing contract with ULB Hold 91.22 96.00 EXMAR Major milestones realised during Q1 Buy 5.76 8.00 GDF Suez One quarter doesn't make the trend reversal Hold 18.19 21.00 Imtech Trading update in line with expectations Buy 21.65 31.00 Mediq Acquires US based D&I company for €12m Buy 11.40 15.00 Mobistar 1Q12E – regulation strikes again Hold 33.00 36.00 Quest for Growth Clear2Pay on the block? Buy 4.23 6.00 Reed Elsevier Reiterates FY12 outlook Accumulate 8.98 11.00 Solvay Ambitious 2016 guidance announced Accumulate 85.83 100.00 Tigenix Cell production facility gets green light Hold 0.57 0.95 Transics Tavares considers take-over bid Buy 6.95 8.00 Umicore FY12 guidance below expectations Hold 41.76 43.00 USG People Double-digit sales decline Accumulate 5.98 11.00 Vopak Preview 1Q12 trading update Hold 47.30 41.00 CHANGES IN RECOMMENDATION CHANGES IN TARGET PRICE Company From To Company From To Umicore Accumulate Hold Umicore 45.00 43.00 KEY FIGURES CHANGES IN EPS FORECAST From To (at close) Price 1D 1M 12M Company 2012 2013 2012 2013 AEX 301.3 -2.6% -7.6% -16.1% Transics (€)
    [Show full text]